HavrileskyLJReinerMMorrowPKet al. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol2015;93:203-10.
2.
WeingartSNFlugJBrouillardDet al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ2007;24:407.
3.
HolleLMPuriSClementJM. Physician-pharmacist collaboration for oral chemotherapy monitoring: insights from an academic genitourinary oncology practice. J Oncol Pharm Pract2016;22:511-6.
4.
ThomaJZelkóRHankóB. The need for community pharmacists in oncology outpatient care: a systematic review. Int J Clin Pharm2016;38:855-62.
5.
BroadfieldLShaheenPRogezMet al. Guidelines for outpatient cancer care by community pharmacists. Can Pharm J (Ott)2016;50:24-31.
6.
ButtFReamE. Implementing oral chemotherapy services in community pharmacies: a qualitative study of chemotherapy nurses’ and pharmacists’ views. Int J Pharm Pract2016;24:149-59.
7.
AbbottREdwardsSWhelanMet al. Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada. J Oncol Pharm Pract2014;20:29-39.
8.
IbrahimNABjörnsdottirIAl AlwanASet al. Insights about health-related quality of life in cancer patients indicate demands for better pharmaceutical care. J Oncol Pharm Pract2014;20:270-7.
9.
van RooijTRixSAntiCMarsh S.: a practice tool for the safe use of oral chemotherapeutics by community and hospital pharmacists. Can Pharm J (Ott)2015;148:118-24.
10.
HämmerleinAGrieseNSchulzM. Survey of drug-related problems identified by community pharmacies. Ann Pharmacother2007;41:1825-32.
11.
SalmanySSRatroutLAmirehAet al. The impact of pharmacist telephone calls after discharge on satisfaction of oncology patients: a randomized controlled study. J Oncol Pharm Pract2017; doi:10.1177/1078155217709616.
12.
WalterCMellorJDRiceCet al. Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic. Asia Pac J Clin Oncol2016;12:e367-74.
13.
GriffinMCGilbertREBroadfieldLHet al. Comparison of independent error checks for oral versus intravenous chemotherapy. J Oncol Pract2016;12:e180-7.
14.
HolleLMHarrisCSChanAet al. Pharmacists’ roles in oncology pharmacy services: results of a global survey. J Oncol Pharm Pract2017;23:185-94.
15.
YokoyamaSYajimaSSakaiCet al. Community pharmacist-led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer. Can Pharm J (Ott)2017;150:362-65.
16.
BaschEJiaXHellerGet al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst2009;101:1624-32.
